Skip to main content
main-content
Erschienen in: Die Ophthalmologie 12/2020

19.11.2020 | Chloroquin | CME

Toxische Retinopathien

verfasst von: Prof. Dr. med. Ulrich Kellner, Simone Kellner, Silke Weinitz, Ghazaleh Farmand

Erschienen in: Die Ophthalmologie | Ausgabe 12/2020

Einloggen, um Zugang zu erhalten

Zusammenfassung

Toxische Retinopathien werden häufig durch externe Stimulanzien (z. B. Nikotin, Poppers, Methanol), seltener durch unerwünschte Arzneimittelwirkungen (UAW) systemisch (z. B. Hydroxychloroquin, Ethambutol, MEK-, ERK-, FLT3-, Checkpointinhibitoren, Didanosin, Pentosanpolysulfat-Natrium) oder intravitreal eingesetzte Medikamente verursacht. Die klinische Symptomatik von UAW ist oft ähnlich zu retinalen Erkrankungen anderer Ursache, sodass die Erkennung von UAW schwierig sein kann. Klinische Befunde, pathophysiologische Mechanismen und, wenn sinnvoll, Screeningstrategien werden diskutiert. Dabei liegt der Fokus auf der Darstellung in der Kausalität gesicherter UAW bei Medikamenten mit bereits langjähriger Zulassung. Bei neuen Medikamenten werden auch kausal ungesicherte Assoziationen dargestellt, um für die weitere Erkennung von UAW bei diesen Medikamenten zu sensibilisieren.
Literatur
1.
Zurück zum Zitat Nita M, Grybowski A (2017) Smoking and eye pathologies. A systematic review. Part II. Retina diseases, uveitis, optic neuropathies, thyroid-associated orbitopathy. Curr Pharm Des 23:639–654 PubMed Nita M, Grybowski A (2017) Smoking and eye pathologies. A systematic review. Part II. Retina diseases, uveitis, optic neuropathies, thyroid-associated orbitopathy. Curr Pharm Des 23:639–654 PubMed
2.
Zurück zum Zitat Cai X, Chen Y, Yang W et al (2018) The association of smoking and risk of diabetic retinopathy in patients with type 1 and type 2 diabetes: a meta-analysis. Endocrine 62:299–306 PubMed Cai X, Chen Y, Yang W et al (2018) The association of smoking and risk of diabetic retinopathy in patients with type 1 and type 2 diabetes: a meta-analysis. Endocrine 62:299–306 PubMed
3.
Zurück zum Zitat Lee DH, Yi HC, Bae SH et al (2018) Risk factors for retinal microvascular impairment in type 2 diabetic patients without diabetic retinopathy. PLoS ONE 13:e202103 PubMedPubMedCentral Lee DH, Yi HC, Bae SH et al (2018) Risk factors for retinal microvascular impairment in type 2 diabetic patients without diabetic retinopathy. PLoS ONE 13:e202103 PubMedPubMedCentral
4.
Zurück zum Zitat Chua SYL, Dhillon B, Aslam T et al (2019) Associations with photoreceptor measurers in the UK Biobank. Sci Rep 9:19440 PubMedPubMedCentral Chua SYL, Dhillon B, Aslam T et al (2019) Associations with photoreceptor measurers in the UK Biobank. Sci Rep 9:19440 PubMedPubMedCentral
5.
Zurück zum Zitat Kotwal A, Stan M (2018) Current and future treatments for and Graves’ Disease and Graves’Ophthalmopathy. Horm Metab Res 50:871–886 PubMed Kotwal A, Stan M (2018) Current and future treatments for and Graves’ Disease and Graves’Ophthalmopathy. Horm Metab Res 50:871–886 PubMed
6.
Zurück zum Zitat Giordano L, Deceglie S, d’Adamo P, Valentino ML (2015) Cigarette toxicity triggers Leber’s hereditary optic neuropathy by affecting mtDNA copy number, oxidative phosphorylation and ROS detoxification pathways. Cell Death Dis 17:e2021 Giordano L, Deceglie S, d’Adamo P, Valentino ML (2015) Cigarette toxicity triggers Leber’s hereditary optic neuropathy by affecting mtDNA copy number, oxidative phosphorylation and ROS detoxification pathways. Cell Death Dis 17:e2021
7.
Zurück zum Zitat El-Shazly AAE, Farweez YAT, Elzankalony YA et al (2018) Effect of smoking on macular function and structure in active smokers versus passive smokers. Retina 38:1031–1040 PubMed El-Shazly AAE, Farweez YAT, Elzankalony YA et al (2018) Effect of smoking on macular function and structure in active smokers versus passive smokers. Retina 38:1031–1040 PubMed
8.
Zurück zum Zitat Yuan N, Li J, Tang S et al (2019) Association of secondhand smoking exposure with choroidal thinning in children aged 6 to 8 years. The Hongkong Children Eye Study. JAMA Ophthalmol 137:1–9 Yuan N, Li J, Tang S et al (2019) Association of secondhand smoking exposure with choroidal thinning in children aged 6 to 8 years. The Hongkong Children Eye Study. JAMA Ophthalmol 137:1–9
10.
Zurück zum Zitat Ashina H, Li XQ, Olsen EM et al (2017) Association of maternal smoking during pregnancy and birth weight with retinal nerve fiber thickness in children aged 11 or 12 years: the Copenhagen Child Cohort 2000 Eye Study. JAMA Ophthalmol 135:331–337 PubMed Ashina H, Li XQ, Olsen EM et al (2017) Association of maternal smoking during pregnancy and birth weight with retinal nerve fiber thickness in children aged 11 or 12 years: the Copenhagen Child Cohort 2000 Eye Study. JAMA Ophthalmol 135:331–337 PubMed
11.
Zurück zum Zitat Rewbury R, Hughes E, Purbrick R et al (2017) Poppers: legal highs with questionable contents? A case series of poppers maculopathy. Br J Ophthalmol 101:1530–1153 PubMed Rewbury R, Hughes E, Purbrick R et al (2017) Poppers: legal highs with questionable contents? A case series of poppers maculopathy. Br J Ophthalmol 101:1530–1153 PubMed
12.
Zurück zum Zitat Nurieva O, Diblik P, Kuthan P et al (2018) Progressive chronic axonal loss following methanol-induced optic neuropathy: four-year prospective cohort study. Am J Ophthalmol 191:100–115 PubMed Nurieva O, Diblik P, Kuthan P et al (2018) Progressive chronic axonal loss following methanol-induced optic neuropathy: four-year prospective cohort study. Am J Ophthalmol 191:100–115 PubMed
13.
Zurück zum Zitat Schlote T, Kellner U (2016) Unerwünschte Arzneimittelwirkungen in der Augenheilkunde: Update 2015/2016. Klin Monbl Augenheilkd 233:203–219 PubMed Schlote T, Kellner U (2016) Unerwünschte Arzneimittelwirkungen in der Augenheilkunde: Update 2015/2016. Klin Monbl Augenheilkd 233:203–219 PubMed
14.
Zurück zum Zitat Tsang SH, Sharma T (2018) Drug-induced retinal toxicity. Adv Exp Med Biol 1085:227–232 PubMed Tsang SH, Sharma T (2018) Drug-induced retinal toxicity. Adv Exp Med Biol 1085:227–232 PubMed
15.
Zurück zum Zitat Bourgeois N, Chavant F, Lafay-Chebassier C et al (2016) Drugs and retinal disorders: a case/non-case study in the French pharmacovigilance database. Therapie 71:365–374 PubMed Bourgeois N, Chavant F, Lafay-Chebassier C et al (2016) Drugs and retinal disorders: a case/non-case study in the French pharmacovigilance database. Therapie 71:365–374 PubMed
16.
Zurück zum Zitat Marmor MF, Kellner U, Lai TY et al (2016) Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology 123:1386–1394 PubMed Marmor MF, Kellner U, Lai TY et al (2016) Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology 123:1386–1394 PubMed
17.
Zurück zum Zitat Melles RB, Marmor MF (2015) Pericentral retinopathy and racial differences in hydroxychloroquine toxicity. Ophthalmology 122:110–116 PubMed Melles RB, Marmor MF (2015) Pericentral retinopathy and racial differences in hydroxychloroquine toxicity. Ophthalmology 122:110–116 PubMed
18.
Zurück zum Zitat Ahn SJ, Joung J, Lim HW, Lee BR (2017) Optical coherence tomography protocols for screening of hydroxychloroquine retinopathy in Asian patients. Am J Ophthalmol 184:11–18 PubMed Ahn SJ, Joung J, Lim HW, Lee BR (2017) Optical coherence tomography protocols for screening of hydroxychloroquine retinopathy in Asian patients. Am J Ophthalmol 184:11–18 PubMed
19.
Zurück zum Zitat Melles RB, Marmor MF (2014) The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol 132:1453–1460 PubMed Melles RB, Marmor MF (2014) The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol 132:1453–1460 PubMed
20.
Zurück zum Zitat Garrity ST, Jung JY, Zambrowski O et al (2019) Early hydroxychloroquine retinopathy: optical coherence tomography abnormalities preceding Humphrey visual field defects. Br J Ophthalmol 103:1600–1604 PubMed Garrity ST, Jung JY, Zambrowski O et al (2019) Early hydroxychloroquine retinopathy: optical coherence tomography abnormalities preceding Humphrey visual field defects. Br J Ophthalmol 103:1600–1604 PubMed
21.
Zurück zum Zitat Kellner S, Weinitz S, Farmand G, Kellner U (2014) Cystoid macular oedema and epiretinal membrane formation during progression of chloroquine retinopathy after drug cessation. Br J Ophthalmol 98:200–206 PubMed Kellner S, Weinitz S, Farmand G, Kellner U (2014) Cystoid macular oedema and epiretinal membrane formation during progression of chloroquine retinopathy after drug cessation. Br J Ophthalmol 98:200–206 PubMed
23.
Zurück zum Zitat Nti AA, Serrano LW, Sandhu HS et al (2019) Frequent subclinical macular changes in combined BRAF/MEK inhibition with high-does hydroxychloroquine as treatment for advanced metastatic BRAF mutant melanoma: Preliminary results from a phase I/II clinical treatment trial. Retina 39:502–513 PubMedPubMedCentral Nti AA, Serrano LW, Sandhu HS et al (2019) Frequent subclinical macular changes in combined BRAF/MEK inhibition with high-does hydroxychloroquine as treatment for advanced metastatic BRAF mutant melanoma: Preliminary results from a phase I/II clinical treatment trial. Retina 39:502–513 PubMedPubMedCentral
25.
Zurück zum Zitat Jain N, Li AL, Yu Y, van der Beek BL (2020) Association of macular disease with long-term use of pentosan polysulfate sodium: findings from a US cohort. Br J Ophthalmol 104:1093–1097 PubMed Jain N, Li AL, Yu Y, van der Beek BL (2020) Association of macular disease with long-term use of pentosan polysulfate sodium: findings from a US cohort. Br J Ophthalmol 104:1093–1097 PubMed
26.
Zurück zum Zitat Vora RA, Patel AP, Melles R (2020) Prevalence of maculopathy associated with long-term pentosan polysulfate therapy. Ophthalmology 127:835–836 PubMed Vora RA, Patel AP, Melles R (2020) Prevalence of maculopathy associated with long-term pentosan polysulfate therapy. Ophthalmology 127:835–836 PubMed
27.
Zurück zum Zitat Shah R, Simonett JM, Lyons RJ et al (2020) Disease course in patients with pentosan polysulfate sodium maculopathy after drug cessation. JAMA Ophthalmol 138:894–900 PubMedPubMedCentral Shah R, Simonett JM, Lyons RJ et al (2020) Disease course in patients with pentosan polysulfate sodium maculopathy after drug cessation. JAMA Ophthalmol 138:894–900 PubMedPubMedCentral
28.
Zurück zum Zitat Zaugg BE, Bell JE, Taylor KY, Bernstein PS (2017) Ezogabine (Potiga) maculopathy. Retin Cases Brief Rep 11:38–43 PubMed Zaugg BE, Bell JE, Taylor KY, Bernstein PS (2017) Ezogabine (Potiga) maculopathy. Retin Cases Brief Rep 11:38–43 PubMed
29.
Zurück zum Zitat Borovik AM, Bosch MM, Watson SL (2009) Ocular pigmentation associated with clozapine. Med J Aust 190:210–211 PubMed Borovik AM, Bosch MM, Watson SL (2009) Ocular pigmentation associated with clozapine. Med J Aust 190:210–211 PubMed
30.
Zurück zum Zitat Baba T, Kubota-Taniai M, Kitahashi M et al (2010) Two-year comparison of photodynamic therapy and intravitreal bevacizumab for treatment of myopic choroidal neovascularisation. Br J Ophthalmol 94:864–870 PubMed Baba T, Kubota-Taniai M, Kitahashi M et al (2010) Two-year comparison of photodynamic therapy and intravitreal bevacizumab for treatment of myopic choroidal neovascularisation. Br J Ophthalmol 94:864–870 PubMed
31.
Zurück zum Zitat Haug SJ, Wong RW, Day S et al (2016) Didanosine retinal toxicity. Retina 36(Suppl 1):S159–S167 PubMed Haug SJ, Wong RW, Day S et al (2016) Didanosine retinal toxicity. Retina 36(Suppl 1):S159–S167 PubMed
32.
Zurück zum Zitat Sophie R, Moses GM, Hwang ES, Kim JE (2019) Fundus hypopigmentation and loss of choroidal nevi pigmentation associated with Nivolumab. JAMA Ophthalmol 137:851–853 PubMed Sophie R, Moses GM, Hwang ES, Kim JE (2019) Fundus hypopigmentation and loss of choroidal nevi pigmentation associated with Nivolumab. JAMA Ophthalmol 137:851–853 PubMed
33.
Zurück zum Zitat Gianni L, Panzini I, Li S et al (2006) International Breast Cancer Study Group. Ocular toxicity during adjuvant chemoendocrine therapy for early breast cancer: results from International Breast Cancer Study Group trials. Cancer 106:505–513 PubMed Gianni L, Panzini I, Li S et al (2006) International Breast Cancer Study Group. Ocular toxicity during adjuvant chemoendocrine therapy for early breast cancer: results from International Breast Cancer Study Group trials. Cancer 106:505–513 PubMed
34.
Zurück zum Zitat Hager T, Seitz B (2013) Ocular side effects of biological agents in oncology: what should the clinician be aware of? Onco Targets Ther 24:69–77 Hager T, Seitz B (2013) Ocular side effects of biological agents in oncology: what should the clinician be aware of? Onco Targets Ther 24:69–77
35.
Zurück zum Zitat Crisostomo S, Vieira L, Cardigos J et al (2020) Tamoxifen-induced chorioretinal changes: an optical coherence tomography and optical tomography angiography study. Retina 40:1185–1190 PubMed Crisostomo S, Vieira L, Cardigos J et al (2020) Tamoxifen-induced chorioretinal changes: an optical coherence tomography and optical tomography angiography study. Retina 40:1185–1190 PubMed
36.
Zurück zum Zitat Wieder MS, Harooni M, Rusu I (2019) Association of crystalline retinopathy with anastrozole. JAMA Ophthalmol 137:581–582 PubMed Wieder MS, Harooni M, Rusu I (2019) Association of crystalline retinopathy with anastrozole. JAMA Ophthalmol 137:581–582 PubMed
37.
Zurück zum Zitat Hueber A, Rosentreter A, Severin M (2011) Canthaxanthion retinopathy: long-term observations. Ophthalmic Res 46:103–106 PubMed Hueber A, Rosentreter A, Severin M (2011) Canthaxanthion retinopathy: long-term observations. Ophthalmic Res 46:103–106 PubMed
38.
Zurück zum Zitat Schlote T, Kellner U (2009) Nebenwirkungen von Medikamenten am Auge. Klin Monbl Augenheilkd 226:173–186 Schlote T, Kellner U (2009) Nebenwirkungen von Medikamenten am Auge. Klin Monbl Augenheilkd 226:173–186
39.
Zurück zum Zitat Moss HE (2017) Visual consequences of medications for multiple sclerosis: the good, the bad, the ugly and the unknown. Eye Brain 29:13–21 Moss HE (2017) Visual consequences of medications for multiple sclerosis: the good, the bad, the ugly and the unknown. Eye Brain 29:13–21
40.
Zurück zum Zitat Heath G, Airody A, Gale RP (2017) The ocular manifestations of drugs used to treat Multiple Sclerosis. Drugs 77:303–311 PubMed Heath G, Airody A, Gale RP (2017) The ocular manifestations of drugs used to treat Multiple Sclerosis. Drugs 77:303–311 PubMed
41.
Zurück zum Zitat Chelala E, Arej N, Antoun J et al (2017) Central macular thickness monitoring after a taxane-based therapy in visually asymptomatic patients. Chemotherapy 62:199–204 PubMed Chelala E, Arej N, Antoun J et al (2017) Central macular thickness monitoring after a taxane-based therapy in visually asymptomatic patients. Chemotherapy 62:199–204 PubMed
42.
Zurück zum Zitat Perez JM, Teo K, Ong R et al (2020) Optical coherence tomography characteristics of taxane-induced macuar edema and other multimodal imaging findings. Graefe Arch. Clin Exp Ophthalmol 258:1607–1615 Perez JM, Teo K, Ong R et al (2020) Optical coherence tomography characteristics of taxane-induced macuar edema and other multimodal imaging findings. Graefe Arch. Clin Exp Ophthalmol 258:1607–1615
43.
Zurück zum Zitat Hu J, Vu JT, Hong B, Gottlieb C (2020) Uveitis and cystoid macular oedema secondary to topical prostaglandin analogue use in ocular hypertension and open-angle glaucoma. Br J Ophthalmol 104:1040–1044 PubMed Hu J, Vu JT, Hong B, Gottlieb C (2020) Uveitis and cystoid macular oedema secondary to topical prostaglandin analogue use in ocular hypertension and open-angle glaucoma. Br J Ophthalmol 104:1040–1044 PubMed
44.
Zurück zum Zitat Shin YK, Lee GW, Kang SW et al (2020) Macular abnormalities associated with 5alpha-reductase inhibitor. JAMA Ophthalmol 138:732–739 PubMed Shin YK, Lee GW, Kang SW et al (2020) Macular abnormalities associated with 5alpha-reductase inhibitor. JAMA Ophthalmol 138:732–739 PubMed
46.
Zurück zum Zitat Araki T, Ishikawa H, Iawhashi C et al (2019) Central serous chorioretinopathy with and without steroids: a multicenter survey. PLoS ONE 24:e213110 Araki T, Ishikawa H, Iawhashi C et al (2019) Central serous chorioretinopathy with and without steroids: a multicenter survey. PLoS ONE 24:e213110
47.
Zurück zum Zitat Aronow ME, Adamus G, Abu-Asab M et al (2012) Paraneoplastic vitelliform retinopathy: clinicopathologic correlation and review of the literature. Surv Ophthalmol 57:558–564 PubMedPubMedCentral Aronow ME, Adamus G, Abu-Asab M et al (2012) Paraneoplastic vitelliform retinopathy: clinicopathologic correlation and review of the literature. Surv Ophthalmol 57:558–564 PubMedPubMedCentral
48.
Zurück zum Zitat Dalvin LA, Jihnson AA, Pulido JS et al (2015) Nonantibestrophin Anti-RPE antibodies in paraneoplastic exudative polymorphous vitelliform maculopathy. Transl Vis Sci Technol 15:4 Dalvin LA, Jihnson AA, Pulido JS et al (2015) Nonantibestrophin Anti-RPE antibodies in paraneoplastic exudative polymorphous vitelliform maculopathy. Transl Vis Sci Technol 15:4
49.
Zurück zum Zitat Van der Noll R, Leijen S, Neuteboom GH et al (2013) Effect of inhibition of the FGFR-MPAK signaling pathway on the development of ocular toxicities. Cancer Treat Rev 39:664–672 PubMed Van der Noll R, Leijen S, Neuteboom GH et al (2013) Effect of inhibition of the FGFR-MPAK signaling pathway on the development of ocular toxicities. Cancer Treat Rev 39:664–672 PubMed
50.
Zurück zum Zitat Booth AEC, Hopkins AM, Rowland A (2020) Risk factors for MEK-associated retinopathy in patients with advanced melanoma treated with combination BRAF and MEK inhibitor therapy. Ther Adv Med Oncol 12:1–10 Booth AEC, Hopkins AM, Rowland A (2020) Risk factors for MEK-associated retinopathy in patients with advanced melanoma treated with combination BRAF and MEK inhibitor therapy. Ther Adv Med Oncol 12:1–10
51.
Zurück zum Zitat Méndez-Martínez S, Calvo P, Ruiz-Moreno O (2019) Ocular adverse events associated with MEK inhibitors. Retina 39:1435–1450 PubMed Méndez-Martínez S, Calvo P, Ruiz-Moreno O (2019) Ocular adverse events associated with MEK inhibitors. Retina 39:1435–1450 PubMed
52.
Zurück zum Zitat Lüdeke I, Terheyden P, Grisanti S, Lüke M (2016) Entwicklung einer serösen Retinopathie unter Behandlung eines metastasierenden kutanen Melanoms. Ophthalmologe 113:861–863 PubMed Lüdeke I, Terheyden P, Grisanti S, Lüke M (2016) Entwicklung einer serösen Retinopathie unter Behandlung eines metastasierenden kutanen Melanoms. Ophthalmologe 113:861–863 PubMed
53.
Zurück zum Zitat Sandhu HS, Kolomeyer AM, Lau MK et al (2017) Acute exudative paraneoplastic polymorphous vitelliform maculopathy during vermurafenib and pembrolizumab treatment for metastatic melanoma. Retin Cases Brief Rep 13:103–107 Sandhu HS, Kolomeyer AM, Lau MK et al (2017) Acute exudative paraneoplastic polymorphous vitelliform maculopathy during vermurafenib and pembrolizumab treatment for metastatic melanoma. Retin Cases Brief Rep 13:103–107
54.
Zurück zum Zitat Sioufi K, Das S, Say EAT (2020) A case of extracellular signal-regulated kinase inhibitor associated retinopathy. JAMA Ophthalmol 138:1002–1004 PubMed Sioufi K, Das S, Say EAT (2020) A case of extracellular signal-regulated kinase inhibitor associated retinopathy. JAMA Ophthalmol 138:1002–1004 PubMed
55.
Zurück zum Zitat Mantopoulus D, Kendra KL, Letson AD, Cebulla CM (2015) Bilateral choroidopathy and serous retinal detachments during ipilimumab treatment for cutaneous melanoma. JAMA Ophthalmol 133:965–967 Mantopoulus D, Kendra KL, Letson AD, Cebulla CM (2015) Bilateral choroidopathy and serous retinal detachments during ipilimumab treatment for cutaneous melanoma. JAMA Ophthalmol 133:965–967
56.
Zurück zum Zitat Dalvin LA, Shields CL, Orloff M et al (2018) Checkpoint inhibitor immune therapy. Systemic indications and ophthalmic side effects. Retina 38:1063–1078 PubMed Dalvin LA, Shields CL, Orloff M et al (2018) Checkpoint inhibitor immune therapy. Systemic indications and ophthalmic side effects. Retina 38:1063–1078 PubMed
58.
Zurück zum Zitat Salgado JP, Khoramnia R, Maier MM et al (2011) Akute Visusminderung während der Therapie einer chronischen Hepatitis C. Ophthalmologe 108:561–564 PubMed Salgado JP, Khoramnia R, Maier MM et al (2011) Akute Visusminderung während der Therapie einer chronischen Hepatitis C. Ophthalmologe 108:561–564 PubMed
59.
Zurück zum Zitat Rentiya ZS, Wells M, Bae J et al (2019) Interferon-α-induced retinopathy in chronic hepatitis C treatment: summary, considerations, and recommendations. Graefes Arch Clin Exp Ophthalmol 257:447–452 PubMed Rentiya ZS, Wells M, Bae J et al (2019) Interferon-α-induced retinopathy in chronic hepatitis C treatment: summary, considerations, and recommendations. Graefes Arch Clin Exp Ophthalmol 257:447–452 PubMed
63.
Zurück zum Zitat Sun MT, Wood MK, Chan WO et al (2017) Risk of intraocular bleeding with novel oral anticoagulants compared with warfarin. A systematic review and meta-analysis. JAMA Ophthalmol 135:864–870 PubMedPubMedCentral Sun MT, Wood MK, Chan WO et al (2017) Risk of intraocular bleeding with novel oral anticoagulants compared with warfarin. A systematic review and meta-analysis. JAMA Ophthalmol 135:864–870 PubMedPubMedCentral
64.
Zurück zum Zitat Treder M, Alnawaiseh M, Wirths G et al (2018) Spontane intraokulare Blutungen unter oraler Antikoagulation: Axipaban in Vergleich zu Phenprocoumon. Ophthalmologe 115:573–578 PubMed Treder M, Alnawaiseh M, Wirths G et al (2018) Spontane intraokulare Blutungen unter oraler Antikoagulation: Axipaban in Vergleich zu Phenprocoumon. Ophthalmologe 115:573–578 PubMed
65.
Zurück zum Zitat Uyhazi KE, Miano T, Pan W et al (2018) Association of novel oral antithrombotics with the risk of intraocular bleeding. JAMA Ophthalmol 136:122–130 PubMed Uyhazi KE, Miano T, Pan W et al (2018) Association of novel oral antithrombotics with the risk of intraocular bleeding. JAMA Ophthalmol 136:122–130 PubMed
66.
Zurück zum Zitat Makuloluwa AK, Tiew S, Briggs M (2019) Peri-operative management of ophthalmic patients on anti-thrombotic agents: a literature review. Eye 33:1044–1059 PubMedPubMedCentral Makuloluwa AK, Tiew S, Briggs M (2019) Peri-operative management of ophthalmic patients on anti-thrombotic agents: a literature review. Eye 33:1044–1059 PubMedPubMedCentral
67.
Zurück zum Zitat Cordero-Coma M, Salazar-Méndez R, Garzo-Garcia I, Yilmaz T (2015) Drug-induced uveitis. Expert Opin Drug Saf 14:111–126 PubMed Cordero-Coma M, Salazar-Méndez R, Garzo-Garcia I, Yilmaz T (2015) Drug-induced uveitis. Expert Opin Drug Saf 14:111–126 PubMed
68.
Zurück zum Zitat Agarwal M, Majumder PD, Babu K et al (2020) Drug-induced uveitis: a review. Indian J Ophthalmol 68:1799–1807 PubMedPubMedCentral Agarwal M, Majumder PD, Babu K et al (2020) Drug-induced uveitis: a review. Indian J Ophthalmol 68:1799–1807 PubMedPubMedCentral
69.
Zurück zum Zitat Keren S, Leibovitch I, Cnaan RB et al (2019) Aminobiphosphonate-associated orbital and ocular inflammatory disease. Acta Ophthalmol 97:e792–e799 PubMed Keren S, Leibovitch I, Cnaan RB et al (2019) Aminobiphosphonate-associated orbital and ocular inflammatory disease. Acta Ophthalmol 97:e792–e799 PubMed
70.
Zurück zum Zitat Lee H, Jin Y, Roh M et al (2020) Risk of cataract surgery and age-related macular degeneration after initiation of Denosumab vs Zolderonic acid for osteoporosis: a multi-database cohort study. Drugs Aging 37:311–320 PubMed Lee H, Jin Y, Roh M et al (2020) Risk of cataract surgery and age-related macular degeneration after initiation of Denosumab vs Zolderonic acid for osteoporosis: a multi-database cohort study. Drugs Aging 37:311–320 PubMed
71.
Zurück zum Zitat Padidam S, Burke MT, Apple DB et al (2019) Association of Ledipasvir-Sofosbuvir treatment with uveitis in patients treated for hepatitis C. JAMA Ophthalmol 137:568–570 PubMedPubMedCentral Padidam S, Burke MT, Apple DB et al (2019) Association of Ledipasvir-Sofosbuvir treatment with uveitis in patients treated for hepatitis C. JAMA Ophthalmol 137:568–570 PubMedPubMedCentral
72.
Zurück zum Zitat Yang MC, Lin KY (2019) Drug-induced acute angle-closure glaucoma: a review. J Curr Glaucoma Pract 13:104–109 PubMedPubMedCentral Yang MC, Lin KY (2019) Drug-induced acute angle-closure glaucoma: a review. J Curr Glaucoma Pract 13:104–109 PubMedPubMedCentral
74.
Zurück zum Zitat Wright T, Kumarappah A, Stavropoulos A et al (2017) Vigabatrin toxicity in infancy is associated with retinal defect in adolescence. Retina 37:858–858 PubMed Wright T, Kumarappah A, Stavropoulos A et al (2017) Vigabatrin toxicity in infancy is associated with retinal defect in adolescence. Retina 37:858–858 PubMed
75.
Zurück zum Zitat Witkin AJ, Chang DF, Jumper MJ et al (2017) Vancomycin-associated hemorrhagic occlusive retinal vasculitis: clinical characteriistics of 36 eyes. Ophthalmology 124:583–595 PubMed Witkin AJ, Chang DF, Jumper MJ et al (2017) Vancomycin-associated hemorrhagic occlusive retinal vasculitis: clinical characteriistics of 36 eyes. Ophthalmology 124:583–595 PubMed
76.
Zurück zum Zitat Bowen RC, Zhou AX, Bondalapati S et al (2018) Comparative analysis of the safety and efficacy of intracameral cefuroxime, moxifloxacin and cancomycin at the end of cataract surgery: a meta-analysis. Br J Ophthalmol 102:1268–1276 PubMed Bowen RC, Zhou AX, Bondalapati S et al (2018) Comparative analysis of the safety and efficacy of intracameral cefuroxime, moxifloxacin and cancomycin at the end of cataract surgery: a meta-analysis. Br J Ophthalmol 102:1268–1276 PubMed
77.
Zurück zum Zitat Penha FM, Rodrigues EB, Furlani BA et al (2011) Toxicological considerations for intravitreal drugs. Expert Opin Drug Metab Toxicol 7:1021–1034 PubMed Penha FM, Rodrigues EB, Furlani BA et al (2011) Toxicological considerations for intravitreal drugs. Expert Opin Drug Metab Toxicol 7:1021–1034 PubMed
78.
Zurück zum Zitat Bracha P, Ciulla TA, Baumal CR (2018) Vital dyes in vitreomacular surgery. Ophthalmic Surg Lasers Imaging Retina 49:788–798 PubMed Bracha P, Ciulla TA, Baumal CR (2018) Vital dyes in vitreomacular surgery. Ophthalmic Surg Lasers Imaging Retina 49:788–798 PubMed
79.
Zurück zum Zitat Fine HF, Reshef ER, Prenner JL et al (2019) Clinical fidnings in triamcinolone-associated maculopathy. Retina 39:761–765 PubMed Fine HF, Reshef ER, Prenner JL et al (2019) Clinical fidnings in triamcinolone-associated maculopathy. Retina 39:761–765 PubMed
80.
Zurück zum Zitat Coco RM, Srivastava GK, André-Iglesias C et al (2019) Acute retinal toxicity associated with a mixture of perfluorooctane and perfluorohexyloctane: failure of another indirect cytotoxicity analysis. Br J Ophthalmol 103:49–54 PubMed Coco RM, Srivastava GK, André-Iglesias C et al (2019) Acute retinal toxicity associated with a mixture of perfluorooctane and perfluorohexyloctane: failure of another indirect cytotoxicity analysis. Br J Ophthalmol 103:49–54 PubMed
81.
Zurück zum Zitat Chamberlain PD, Sadaka A, Berry S, Lee AG (2017) Ethambutol-optic neuropathy. Curr Opin Ophthalmol 28:545–551 PubMed Chamberlain PD, Sadaka A, Berry S, Lee AG (2017) Ethambutol-optic neuropathy. Curr Opin Ophthalmol 28:545–551 PubMed
83.
Zurück zum Zitat Alsheri M, Joury A (2020) Oculr adverse effects of amiodaronea systematic review of case reports. Optom Vis Sci 97:536–542 Alsheri M, Joury A (2020) Oculr adverse effects of amiodaronea systematic review of case reports. Optom Vis Sci 97:536–542
84.
Zurück zum Zitat Sotgiu G, Centis R, D’Ambrosio L et al (2012) Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respi J 40:1430–1442 Sotgiu G, Centis R, D’Ambrosio L et al (2012) Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respi J 40:1430–1442
85.
Zurück zum Zitat Jaspard M, Butel N, El Helali N et al (2020) Linezolid-associated neurologic adverse events in patients with multidrug-resistant tuberculosis, France. Emerg Infect Dis 26:1792–1800 PubMedPubMedCentral Jaspard M, Butel N, El Helali N et al (2020) Linezolid-associated neurologic adverse events in patients with multidrug-resistant tuberculosis, France. Emerg Infect Dis 26:1792–1800 PubMedPubMedCentral
Metadaten
Titel
Toxische Retinopathien
verfasst von
Prof. Dr. med. Ulrich Kellner
Simone Kellner
Silke Weinitz
Ghazaleh Farmand
Publikationsdatum
19.11.2020
Verlag
Springer Medizin
Erschienen in
Die Ophthalmologie / Ausgabe 12/2020
Print ISSN: 2731-720X
Elektronische ISSN: 2731-7218
DOI
https://doi.org/10.1007/s00347-020-01260-w